Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sudarshan Pharma
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 99 | 129 | 116 | 162 | 145 | 169 | 168 | 221 |
| Expenses + | 97 | 116 | 108 | 146 | 134 | 160 | 157 | 201 |
| Operating Profit | 2 | 13 | 8 | 16 | 11 | 9 | 11 | 20 |
| OPM % | 2% | 10% | 7% | 10% | 8% | 5% | 6% | 9% |
| Other Income + | 1 | -1 | 1 | -1 | 1 | 2 | 2 | 4 |
| Interest | 4 | 4 | 4 | 4 | 6 | 6 | 6 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -2 | 8 | 4 | 10 | 5 | 4 | 5 | 16 |
| Tax % | -22% | 25% | 25% | 25% | 27% | 9% | 20% | 27% |
| Net Profit + | -1 | 6 | 3 | 7 | 4 | 4 | 4 | 11 |
| EPS in Rs | -0.05 | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 |
Financials of Sudarshan Pharma
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 148 | 193 | 357 | 461 | 464 | 505 | 703 |
| Expenses + | 143 | 186 | 346 | 446 | 441 | 465 | 652 |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 |
| OPM % | 3% | 4% | 3% | 3% | 5% | 8% | 7% |
| Other Income + | 0 | 0 | 0 | 1 | 3 | -0 | 9 |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 26 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 4 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 22 | 31 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | 23% |
| Net Profit + | 1 | 3 | 5 | 7 | 11 | 16 | 23 |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 |
| Dividend Payout % | 0% | 0% | 0% | 10% | 0% | 0% | 0% |
Financials of Sudarshan Pharma
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| Borrowings + | 21 | 30 | 31 | 34 | 105 | 171 | 285 |
| Other Liabilities + | 18 | 47 | 77 | 97 | 67 | 100 | 202 |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| Fixed Assets + | 6 | 6 | 6 | 20 | 26 | 24 | 104 |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| Other Assets + | 53 | 93 | 131 | 200 | 242 | 342 | 534 |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Financials of Sudarshan Pharma
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | 3 | -4 | -29 | 8 | 35 | -2 |
| Cash from Investing Activity + | -3 | -1 | -1 | -26 | -7 | -20 | -78 |
| Cash from Financing Activity + | -0 | -1 | 4 | 66 | -12 | -14 | 79 |
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 | 0 | -1 |
| Free Cash Flow | -4 | 1 | -5 | -43 | 4 | 30 | -51 |
| CFO/OP | 20% | 50% | -19% | -179% | 43% | 96% | 7% |
Financials of Sudarshan Pharma
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working Capital Days | 35 | 29 | 27 | 54 | 59 | 53 | 17 |
| ROCE % | 15% | 19% | 15% | 14% | 16% | 15% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…